Dr. John Crew Gives Grand Rounds Presentation on Treating Wounds With NovaBay's NeutroPhase at Eisenhower Medical Center
06. Februar 2014 08:30 ET
|
NovaBay Pharmaceuticals, Inc.
Dr. Crew Describes How His Breakthrough Treatment Using NeutroPhase is Saving the Lives and Limbs of Patients With Deadly 'Flesh-eating Disease'
EMERYVILLE, Calif., Feb. 6, 2014 (GLOBE NEWSWIRE)...
NovaBay Pharmaceuticals to Present at BIO CEO & Investor Conference
03. Februar 2014 08:30 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 3, 2014 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial...
Research Breakthrough for Deadly Flesh-Eating Disease Reported in the Journal Cell Highlights Importance of Neutralization of Toxins Associated With Flesh-Eating Bacteria
28. Januar 2014 08:30 ET
|
NovaBay Pharmaceuticals, Inc.
http://www.jpost.com/Health-and-Science/Hebrew-University-researchers-explain-how-innocent-bacteria-can-cause-flesh-eating-disease-338459
EMERYVILLE, Calif., Jan. 28, 2014 (GLOBE NEWSWIRE) --...
Photo Release -- NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek, Solta Medical Chairman and CEO and Dr. Massimo Radaelli, Noventia Pharma CEO to Its Board of Directors
09. Januar 2014 08:30 ET
|
NovaBay Pharmaceuticals, Inc.
Combined Total of Over 50 Years of Healthcare Experience in Global Markets Adds Significant Depth to NovaBay's Board
EMERYVILLE, Calif., Jan. 9 2014 (GLOBE NEWSWIRE) -- NovaBay®...
NovaBay Pharmaceuticals Provides Business Unit Update and 2014 Outlook
08. Januar 2014 08:30 ET
|
NovaBay Pharmaceuticals, Inc.
Urology
Reported Positive Phase 2 Clinical Study Results of Auriclosene to Reduce Urinary Catheter Blockage and Encrustation (UCBE)
Ophthalmology
Completion of Global Conjunctivitis Clinical...
NovaBay Pharmaceuticals Announces Plan to Reinitiate Clinical Evaluation of Auriclosene for Impetigo in 2014
19. Dezember 2013 08:00 ET
|
NovaBay Pharmaceuticals, Inc.
Impetigo Clinical Program Moves Forward With Optimized Formulation
EMERYVILLE, Calif., Dec. 19, 2013 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage...
Dr. Ron Najafi, CEO of NovaBay Pharmaceuticals, Urges FDA to Formally Ban Antibiotic Use in Food Production
12. Dezember 2013 08:30 ET
|
NovaBay Pharmaceuticals, Inc.
FDA's Recently Announced Plan to Curb Antibiotic Use in Animals is Merely Voluntary and Should go Further
NovaBay Calls for Labeling of Antibiotic-fed Meats
EMERYVILLE, Calif., Dec. 12, 2013...
NovaBay Pharmaceuticals Gains ISO 13485 Certification for the Design and Manufacturing of NeutroPhase(R)
11. Dezember 2013 08:30 ET
|
NovaBay Pharmaceuticals, Inc.
Company Meets Internationally Recognized Quality and Regulatory Standards
EMERYVILLE, Calif., Dec. 11, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage...
NovaBay Pharmaceuticals and China Pioneer Pharma Announce Expansion of Partnership Agreement
02. Dezember 2013 09:02 ET
|
NovaBay Pharmaceuticals, Inc.
Pioneer to License Rights to Commercialize Two New NovaBay Products In China and Southeast Asia
NovaBay to Receive $5.7 Million Equity Investment from China Pioneer Pharma
EMERYVILLE, Calif.,...
NovaBay Pharmaceuticals Reports Third Quarter 2013 Financial Results and a Clinical/Business Update
14. November 2013 09:20 ET
|
NovaBay Pharmaceuticals, Inc.
Phase 2b study of Auriclosene for Impetigo Completed by Partner Galderma
Reported Positive Results from Phase 2 Clinical Study of Auriclosene to Reduce Urinary Catheter Blockage and Encrustation...